Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994927 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
NCT02994927 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 331 participants.
The verdict
NCT02994927, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.
Interventions
- DRUG Cyclophosphamide
- DRUG Prednisone
- BIOLOGICAL Rituximab
- DRUG Azathioprine
- DRUG Avacopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2019-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02994927
The ClinicalTrials.gov registry entry for NCT02994927 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02994927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02994927 about?
NCT02994927 is a clinical study titled "A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis". The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with ritu...
What is the current status of trial NCT02994927?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2017-03-15. Estimated completion is 2019-11-01.
What interventions are being tested in trial NCT02994927?
The interventions under investigation include: Cyclophosphamide (DRUG), Prednisone (DRUG), Rituximab (BIOLOGICAL), Azathioprine (DRUG), Avacopan (DRUG).
Who is sponsoring clinical trial NCT02994927?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.